TBPH — Theravance Biopharma Inc USA
[[ lastPrice | number : 2]]
[[ refundPrice | number : 2]]
[[ refundPriceP | number : 2]]%
[[ refundPriceP | number : 2]]%
[[ lastDate * 1000 | date:'MMM d, y @h:mm a' ]]
Currency in USD
Currency in USD
Basic
Not enough data for Expected Return.
Not enough data for Risks (Volatility).
Not enough data for Beta calculations.
Market capital
$665M
Employees
158
Money
Not enough data for Earnings per share statistics.
Not enough data for Book Value calculations.
Wall Street price
$10.33
PE Ratio
—
Dividends
$0.00
Volume & Social
Short Ratio
14.36%
Daily Volume
720,457
Volume
Average
Social Rate
Untracked
Social Volume
Untracked
Latest TBPH news
[[ item.source ]]
-
[[ item.pubDate | date:'MMM d, y @ h:mma' ]]
[[ item.description ]]
Invest ideas
Invest Ideas — the best way to get insights based on both fundamental and technical data.
We analyze company's performance across sector and industry and generate investing ideas for you.
Want to track signal changes?
It's easy to monitor changes in signal with our
watchlist. Just add the stock to your watchlist
and get daily, weekly and monthly signal changes for the asset.
Most and less correlated stocks. All correllations are calculated for 1 year period.
Learn more
about correlations.
Similar (most correlated) stocks
Correlation
94.80%
UB Rating
Correlation
92.00%
UB Rating
Correlation
91.20%
UB Rating
Correlation
90.70%
UB Rating
Correlation
90.60%
UB Rating
Correlation
90.50%
UB Rating
Correlation
90.50%
UB Rating
Correlation
90.20%
UB Rating
Correlation
89.90%
UB Rating
Correlation
89.80%
UB Rating
Opposite (less correlated) stocks
Correlation
−95.30%
UB Rating
Correlation
−95.30%
UB Rating
Correlation
−93.10%
UB Rating
Correlation
−92.90%
UB Rating
Correlation
−92.30%
UB Rating
Correlation
−91.80%
UB Rating
Correlation
−91.70%
UB Rating
Correlation
−91.60%
UB Rating
Correlation
−91.20%
UB Rating
Correlation
−91.10%
UB Rating
| All numbers in thousands | [[fin.date | strtotimestamp | date: 'MMM d, yyyy']] |
| Revenue | |
| Total Revenue | [[fin.totalRevenue / 1000 | number : 0]] |
| Cost of Revenue | [[fin.costOfRevenue / 1000 | number : 0]] |
| Gross Profit | [[fin.grossProfit / 1000 | number : 0]] |
| Operating Expenses | |
| Research Development | [[fin.researchDevelopment / 1000 | number : 0]] |
| Selling General and Administrative | [[fin.sellingGeneralAdministrative / 1000 | number : 0]] |
| Non Recurring | [[fin.nonRecurring / 1000 | number : 0]] |
| Others | [[fin.otherOperatingExpenses / 1000 | number : 0]] |
| Total Operating Expenses | [[fin.totalOperatingExpenses / 1000 | number : 0]] |
| Operating Income or Loss | [[fin.operatingIncome / 1000 | number : 0]] |
| Income from Continuing Operations | |
| Total Other Income/Expenses Net | [[fin.totalOtherIncomeExpenseNet / 1000 | number : 0]] |
| Earnings Before Interest and Taxes | [[fin.ebit / 1000 | number : 0]] |
| Interest Expense | [[fin.interestExpense / 1000 | number : 0]] |
| Income Before Tax | [[fin.incomeBeforeTax / 1000 | number : 0]] |
| Income Tax Expense | [[fin.incomeTaxExpense / 1000 | number : 0]] |
| Minority Interest | [[fin.minorityInterest / 1000 | number : 0]] |
| Net Income From Continuing Ops | [[fin.netIncomeFromContinuingOps / 1000 | number : 0]] |
| Non-recurring Events | |
| Discontinued Operations | [[fin.discontinuedOperations / 1000 | number : 0]] |
| Extraordinary Items | [[fin.extraordinaryItems / 1000 | number : 0]] |
| Effect Of Accounting Changes | [[fin.effectOfAccountingCharges / 1000 | number : 0]] |
| Other Items | [[fin.otherItems / 1000 | number : 0]] |
| Net Income | |
| Net Income | [[fin.netIncome / 1000 | number : 0]] |
| Net Income Applicable To Common Shares | [[fin.netIncomeApplicableToCommonShares / 1000 | number : 0]] |
| All numbers in thousands | [[fin.date | strtotimestamp | date: 'MMM d, yyyy']] |
| Current Assets | |
| Cash And Cash Equivalents | [[fin.cash / 1000 | number : 0]] |
| Short Term Investments | [[fin.shortTermInvestments / 1000 | number : 0]] |
| Net Receivables | [[fin.netReceivables/ 1000 | number : 0]] |
| Inventory | [[fin.inventory/ 1000 | number : 0]] |
| Other Current Assets | [[fin.otherCurrentAssets/ 1000 | number : 0]] |
| Total Current Assets | [[fin.totalCurrentAssets / 1000 | number : 0]] |
| Long Term Investments | [[fin.longTermInvestments / 1000 | number : 0]] |
| Property Plant and Equipment | [[fin.propertyPlantEquipment / 1000 | number : 0]] |
| Goodwill | [[fin.goodWill / 1000 | number : 0]] |
| Intangible Assets | [[fin.intangibleAssets / 1000 | number : 0]] |
| Other Assets | [[fin.otherAssets / 1000 | number : 0]] |
| Total Assets | [[fin.totalAssets / 1000 | number : 0]] |
| Current Liabilities | |
| Accounts Payable | [[fin.accountsPayable / 1000 | number : 0]] |
| Short/Current Long Term Debt | [[fin.shortLongTermDebt / 1000 | number : 0]] |
| Other Current Liabilities | [[fin.otherCurrentLiab / 1000 | number : 0]] |
| Total Current Liabilities | [[fin.totalCurrentLiabilities / 1000 | number : 0]] |
| Long Term Debt | [[fin.longTermDebt / 1000 | number : 0]] |
| Other Liabilities | [[fin.otherLiab / 1000 | number : 0]] |
| Deferred Long Term Liability Charges | [[fin.deferredLongTermLiab / 1000 | number : 0]] |
| Total Liabilities | [[fin.totalLiab / 1000 | number : 0]] |
| Stockholders' Equity | |
| Common Stock | [[fin.commonStock / 1000 | number : 0]] |
| Retained Earnings | [[fin.retainedEarnings / 1000 | number : 0]] |
| Other Stockholder Equity | [[fin.otherStockholderEquity / 1000 | number : 0]] |
| Total Stockholder Equity | [[fin.totalStockholderEquity / 1000 | number : 0]] |
| Net Tangible Assets | [[fin.netTangibleAssets / 1000 | number : 0]] |
| All numbers in thousands | [[fin.date | strtotimestamp | date: 'MMM d, yyyy']] |
| Net Income | [[fin.netIncome/ 1000 | number : 0]] |
| Operating Activities, Cash Flows Provided By or Used In | |
| Depreciation | [[fin.depreciation / 1000 | number : 0]] |
| Adjustments To Net Income | [[fin.changeToNetincome / 1000 | number : 0]] |
| Changes In Accounts Receivables | [[fin.changeToAccountReceivables / 1000 | number : 0]] |
| Changes In Liabilities | [[fin.changeToLiabilities / 1000 | number : 0]] |
| Changes In Inventories | [[fin.changeToInventory / 1000 | number : 0]] |
| Changes In Other Operating Activities | [[fin.changeToOperatingActivities / 1000 | number : 0]] |
| Total Cash Flow From Operating Activities | [[fin.totalCashFromOperatingActivities / 1000 | number : 0]] |
| Investing Activities, Cash Flows Provided By or Used In | |
| Capital Expenditures | [[fin.capitalExpenditures / 1000 | number : 0]] |
| Investments | [[fin.investments / 1000 | number : 0]] |
| Other Cash flows from Investing Activities | [[fin.otherCashflowsFromInvestingActivities / 1000 | number : 0]] |
| Total Cash Flows From Investing Activities | [[fin.totalCashflowsFromInvestingActivities / 1000 | number : 0]] |
| Financing Activities, Cash Flows Provided By or Used In | |
| Dividends Paid | [[fin.dividendsPaid / 1000 | number : 0]] |
| Sale Purchase of Stock | [[fin.salePurchaseOfStock / 1000 | number : 0]] |
| Net Borrowings | [[fin.netBorrowings / 1000 | number : 0]] |
| Other Cash Flows from Financing Activities | [[fin.otherCashflowsFromFinancingActivities / 1000 | number : 0]] |
| Total Cash Flows From Financing Activities | [[fin.totalCashFromFinancingActivities / 1000 | number : 0]] |
| Change In Cash and Cash Equivalents | [[fin.changeInCash / 1000 | number : 0]] |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
| Avg | 0.14 | 0.12 | 0.38 |
| High | 0.17 | 0.30 | 1.12 |
| Low | 0.12 | 0.01 | -0.01 |
| Avg | 13.3M | 61.0M | 73.2M |
| High | 15.6M | 105M | 110M |
| Low | 11.0M | 47.9M | 48.5M |
| [[fin.date | strtotimestamp | date: 'MMM d,yyyy']] | |
| Earnings History | |
| Earnings Actual | [[fin.epsActual | number : 2]] |
| Earnings Estimate | [[fin.epsEstimate | number : 2]] |
| Difference | [[fin.epsDifference | number : 2]] |
| Surprise | [[fin.surprisePercent | number : 1]]% |
| Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) | |
| Earnings Estimate | ||||
| Number of Analysts | [[financials['etrend']['0q'].earningsEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1q'].earningsEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['0y'].earningsEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1y'].earningsEstimateNumberOfAnalysts | number : 0]] |
| Estimate Average | [[financials['etrend']['0q'].earningsEstimateAvg | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateAvg | number : 2]] | [[financials['etrend']['0y'].earningsEstimateAvg | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateAvg | number : 2]] |
| Estimate High | [[financials['etrend']['0q'].earningsEstimateHigh | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateHigh | number : 2]] | [[financials['etrend']['0y'].earningsEstimateHigh | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateHigh | number : 2]] |
| Estimate Low | [[financials['etrend']['0q'].earningsEstimateLow | number : 2]] | [[financials['etrend']['0q'].earningsEstimateLow | number : 2]] | [[financials['etrend']['0y'].earningsEstimateLow | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateLow | number : 2]] |
| Estimate Growth | [[financials['etrend']['0q'].earningsEstimateGrowth | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateGrowth | number : 2]] | [[financials['etrend']['0y'].earningsEstimateGrowth | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateGrowth | number : 2]] |
| Year Ago EPS | [[financials['etrend']['0q'].earningsEstimateYearAgoEps | number : 2]] | [[financials['etrend']['+1q'].earningsEstimateYearAgoEps | number : 2]] | [[financials['etrend']['0y'].earningsEstimateYearAgoEps | number : 2]] | [[financials['etrend']['+1y'].earningsEstimateYearAgoEps | number : 2]] |
| All numbers in thousands (except analysts) | Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) |
| Revenue Estimate | ||||
| Number of Analysts | [[financials['etrend']['0q'].revenueEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['0y'].revenueEstimateNumberOfAnalysts | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateNumberOfAnalysts | number : 0]] |
| Estimate Average | [[financials['etrend']['0q'].revenueEstimateAvg / 1000 | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateAvg / 1000 | number : 0]] | [[financials['etrend']['0y'].revenueEstimateAvg / 1000 | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateAvg / 1000 | number : 0]] |
| Estimate High | [[financials['etrend']['0q'].revenueEstimateHigh / 1000 | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateHigh / 1000 | number : 0]] | [[financials['etrend']['0y'].revenueEstimateHigh / 1000 | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateHigh / 1000 | number : 0]] |
| Estimate Low | [[financials['etrend']['0q'].revenueEstimateLow / 1000 | number : 0]] | [[financials['etrend']['0q'].revenueEstimateLow / 1000 | number : 0]] | [[financials['etrend']['0y'].revenueEstimateLow / 1000 | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateLow / 1000 | number : 0]] |
| Estimate Growth | [[financials['etrend']['0q'].revenueEstimateGrowth * 100 | number : 2]]% | [[financials['etrend']['+1q'].revenueEstimateGrowth * 100 | number : 2]]% | [[financials['etrend']['0y'].revenueEstimateGrowth * 100 | number : 2]]% | [[financials['etrend']['+1y'].revenueEstimateGrowth * 100| number : 2]]% |
| Year Ago EPS | [[financials['etrend']['0q'].revenueEstimateYearAgoEps | number : 0]] | [[financials['etrend']['+1q'].revenueEstimateYearAgoEps | number : 0]] | [[financials['etrend']['0y'].revenueEstimateYearAgoEps | number : 0]] | [[financials['etrend']['+1y'].revenueEstimateYearAgoEps | number : 0]] |
| Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) | |
| EPS Trend | ||||
| Current Estimate | [[financials['etrend']['0q'].epsTrendCurrent | number : 2]] | [[financials['etrend']['+1q'].epsTrendCurrent | number : 2]] | [[financials['etrend']['0y'].epsTrendCurrent | number : 2]] | [[financials['etrend']['+1y'].epsTrendCurrent | number : 2]] |
| 7 Days Ago | [[financials['etrend']['0q'].epsTrend7daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend7daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend7daysAgo| number : 2]] | [[financials['etrend']['+1y'].epsTrend7daysAgo | number : 2]] |
| 30 Days Ago | [[financials['etrend']['0q'].epsTrend30daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend30daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend30daysAgo | number : 2]] | [[financials['etrend']['+1y'].epsTrend30daysAgo | number : 2]] |
| 60 Days Ago | [[financials['etrend']['0q'].epsTrend60daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend60daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend60daysAgo | number : 2]] | [[financials['etrend']['+1y'].epsTrend60daysAgo | number : 2]] |
| 90 Days Ago | [[financials['etrend']['0q'].epsTrend90daysAgo | number : 2]] | [[financials['etrend']['+1q'].epsTrend90daysAgo | number : 2]] | [[financials['etrend']['0y'].epsTrend90daysAgo | number : 2]] | [[financials['etrend']['+1y'].epsTrend90daysAgo | number : 2]] |
| Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) | Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) | Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']]) | |
| EPS Revisions | ||||
| Up Last 7 Days | [[financials['etrend']['0q'].epsRevisionsUpLast7days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsUpLast7days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsUpLast7days | number : 0]] | [[financials['etrend']['+1y'].epsRevisionsUpLast7days | number : 0]] |
| Up Last 30 Days | [[financials['etrend']['0q'].epsRevisionsUpLast30days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsUpLast30days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsUpLast30days| number : 0]] | [[financials['etrend']['+1y'].epsRevisionsUpLast30days | number : 0]] |
| Down Last 30 Days | [[financials['etrend']['0q'].epsRevisionsDownLast7days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsDownLast7days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsDownLast7days | number : 0]] | [[financials['etrend']['+1y'].epsRevisionsDownLast7days | number : 0]] |
| Down Last 90 Days | [[financials['etrend']['0q'].epsRevisionsDownLast30days | number : 0]] | [[financials['etrend']['+1q'].epsRevisionsDownLast30days | number : 0]] | [[financials['etrend']['0y'].epsRevisionsDownLast30days | number : 0]] | [[financials['etrend']['+1y'].epsRevisionsDownLast30days | number : 0]] |